Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIUMPH-2 trientine formulation crossover pharmacokinetics study
NL-OMON43154Phase 1Active, not recruiting
- Sponsor
- Orphalan
- Start
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of trientine and trientine tetrahydrochloride in Wilson disease (WD) (4 arms), sponsored by Orphalan. Primary endpoints: Pharmacokinetic parameters of TETA, Pharmacokinetic parameters of MAT and 1 more. Started Oct 2016; status: active, not recruiting.
02
Drugs
trientinetrientine tetrahydrochloride
03
Conditions
Wilson disease (WD)
Beyond the preview
Go deeper on NL-OMON43154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43154.